Plant Name: Tulipa sylvestris
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| GPBAR1; ADORA3; | |
| PTPN1; PTPN2; ACP1; PTPRF; CDC25B; | |
| PLA2G1B; RECQL; TDP1; PKM; HSD11B1; HSD17B1; NOX4; AKR1B10; ALOX15; USP2; TNKS; TNKS2; POLB; | |
| ACHE; | |
| CFTR; | |
| GSK3B; SYK; FLT3; CDK6; CSNK2A1; | |
| AR; | |
| RORC; | |
| ESR2; ESR1; | |
| NR1H4; | |
| MAOA; PTGS2; XDH; | |
| TP53; HIF1A; | |
| ABCG2; ABCC1; | |
| SLCO1B3; SLCO1B1; | |
| NPC1; MAPT; THPO; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 6.031E-11 | 3.283E-07 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4, RORC |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.882E-09 | 2.345E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.405E-09 | 3.531E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.957E-09 | 5.411E-06 | CFTR, HIF1A, NPC1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.278E-08 | 1.378E-05 | AR, CFTR, CYP1A1, CYP1B1, ESR1, FLT3, NOX4, NPC1, PTGS2, RORC |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.322E-08 | 2.241E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 5.013E-08 | 2.375E-05 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.000E-07 | 7.138E-05 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.809E-07 | 1.220E-04 | CDK6, CFTR, HIF1A, NPC1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 8.050E-07 | 2.213E-04 | CDK6, GSK3B, HIF1A, MAPT, PTGS2, PTPN1, PTPN2, PTPRF, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.287E-06 | 3.209E-04 | ABCC1, ALOX15, PLA2G1B, SYK |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.054E-06 | 4.659E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 2.669E-06 | 5.698E-04 | ALOX15, PLA2G1B, PTGS2, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.819E-06 | 5.925E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.894E-06 | 7.771E-04 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 3.926E-06 | 7.771E-04 | AR, CDK6, CFTR, ESR1, FLT3, NPC1, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 6.224E-06 | 1.111E-03 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 6.835E-06 | 1.181E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 2.047E-05 | 2.932E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.047E-05 | 2.932E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.047E-05 | 2.932E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 2.047E-05 | 2.932E-03 | GPBAR1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.230E-05 | 3.153E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.230E-05 | 3.153E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 2.342E-05 | 3.291E-03 | AR, ESR1, ESR2, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.959E-05 | 4.052E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 3.829E-05 | 4.933E-03 | ABCC1, ABCG2, NPC1, SLCO1B1, SLCO1B3 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 4.087E-05 | 5.057E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 4.087E-05 | 5.057E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.087E-05 | 5.057E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.087E-05 | 5.057E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.087E-05 | 5.057E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 4.319E-05 | 5.314E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0072330; monocarboxylic acid biosynthetic process | 4.364E-05 | 5.339E-03 | ALOX15, CYP1A1, PKM, PLA2G1B, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 4.850E-05 | 5.803E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 5.422E-05 | 6.382E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 5.422E-05 | 6.382E-03 | MAPT, PTPN1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 5.957E-05 | 6.723E-03 | CYP1A1, HIF1A, NOX4, PKM, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:2001242; regulation of intrinsic apoptotic signaling pathway | 5.959E-05 | 6.723E-03 | HIF1A, PTGS2, PTPN1, PTPN2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0035774; positive regulation of insulin secretion involved in cellular response to glucose stimulus | 6.036E-05 | 6.741E-03 | CFTR, HIF1A, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 6.326E-05 | 6.887E-03 | AR, ESR1, ESR2, NR1H4, RORC |
| MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 6.476E-05 | 7.016E-03 | AR, CSNK2A1, ESR1, GSK3B |
| BP | GO:0051179; localization | GO:0015721; bile acid and bile salt transport | 6.695E-05 | 7.162E-03 | NR1H4, SLCO1B1, SLCO1B3 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.800E-05 | 7.188E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0070372; regulation of ERK1 and ERK2 cascade | 8.131E-05 | 8.252E-03 | ALOX15, NOX4, PTPN1, PTPN2, SYK, THPO |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.148E-05 | 8.252E-03 | CSNK2A1, HIF1A, MAPT |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 8.315E-05 | 8.382E-03 | ADORA3, AR, CDK6, CYP1B1, NOX4, PTGS2, PTPN2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 8.809E-05 | 8.758E-03 | AR, CSNK2A1, ESR1, ESR2, GSK3B, HIF1A, MAPT, NPC1, NR1H4, PTGS2, PTPN1, PTPN2, RORC, TNKS, TNKS2, TP53, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 9.315E-05 | 9.220E-03 | AKR1B10, CYP1A1, CYP1B1, TTR |
| BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 9.641E-05 | 9.437E-03 | ALOX15, AR, CDK6, CYP19A1, ESR1, ESR2, GSK3B, HIF1A, NR1H4, PTGS2, PTPN1, PTPN2, XDH |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 9.664E-05 | 9.437E-03 | AR, ESR1, ESR2, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.018E-04 | 9.725E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.018E-04 | 9.725E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.244E-10 | 1.729E-08 | HSD11B1; HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.561E-08 | 1.780E-06 | SLCO1B1; SLCO1B3; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.713E-07 | 5.952E-06 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.131E-08 | 2.841E-06 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.162E-06 | 2.692E-05 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.687E-06 | 1.683E-04 | PLA2G1B; MAOA; ALOX15; PTGS2; CYP3A4; CYP19A1; HSD11B1; PKM; AKR1B10; HSD17B1; CYP1A2; CYP1A1; XDH |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.202E-06 | 6.359E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.497E-07 | 2.362E-05 | PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.281E-05 | 7.349E-04 | AR; GSK3B; CDK6; FLT3; PTGS2; HIF1A; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.553E-05 | 3.943E-04 | PKM; FLT3; TP53; HIF1A |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.782E-05 | 5.258E-04 | PTPN1; CSNK2A1; ACP1; PTPRF |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.047E-04 | 1.120E-03 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; CDC25B |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.726E-04 | 1.713E-03 | POLB; CDK6; PKM; SYK; TP53 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.323E-04 | 2.018E-03 | GSK3B; TP53; ESR1; HIF1A |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.990E-04 | 3.081E-03 | GSK3B; CDK6; CSNK2A1; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.808E-04 | 2.296E-03 | GSK3B; CDK6; TP53; CDC25B |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.313E-04 | 3.887E-03 | PLA2G1B; ALOX15; PTGS2 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.922E-04 | 1.781E-03 | ABCC1; CFTR; ABCG2 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 8.230E-04 | 5.200E-03 | GSK3B; ESR1; ESR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.104E-04 | 4.242E-03 | CYP1A2; CYP1A1; CYP3A4 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.742E-03 | 9.312E-03 | GSK3B; SYK; CSNK2A1; TP53 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.269E-04 | 4.811E-03 | MAOA; CYP1A2; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.520E-03 | 8.804E-03 | GSK3B; AR; TP53 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.377E-03 | 8.324E-03 | CDK6; PTGS2; TP53 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.711E-03 | 1.396E-02 | PTPN1; GSK3B; PTPRF |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.725E-03 | 9.312E-03 | SYK; CSNK2A1; PTGS2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.928E-03 | 1.454E-02 | MAOA; ALOX15; PTGS2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.557E-03 | 1.705E-02 | ABCC1; ADORA3; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.689E-03 | 2.551E-02 | GSK3B; CSNK2A1; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 5.362E-03 | 2.485E-02 | PTPN1; GSK3B; PTPRF |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.106E-02 | 4.044E-02 | GSK3B; CDK6; SYK; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.501E-02 | 4.637E-02 | TP53; HIF1A; ESR1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 7.793E-03 | 3.282E-02 | GSK3B; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.197E-02 | 4.266E-02 | CDK6; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.992E-03 | 3.472E-02 | PTGS2; TSHR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.992E-03 | 3.472E-02 | CDK6; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.093E-02 | 4.044E-02 | GSK3B; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.232E-02 | 4.282E-02 | CDK6; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.493E-02 | 4.637E-02 | GSK3B; SYK |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.416E-02 | 4.637E-02 | CDK6; TP53 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 8.685E-03 | 3.472E-02 | GSK3B; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.493E-02 | 4.637E-02 | CDK6; TP53 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.341E-02 | 4.547E-02 | CDK6; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 6.142E-03 | 2.668E-02 | CYP3A4; XDH |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.344E-05 | 7.349E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; PLA2G1B; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PLA2G1B; PTGS2 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; HSD11B1; HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; SYK; ADORA3; TP53; FLT3; FLT3; ACHE; ESR1; ESR1; PTGS2; CSNK2A1; CDC25B |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; PTGS2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; FLT3; PKM |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ACHE |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; PTGS2; PTGS2; ABCC1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; PLA2G1B; PTGS2; PTGS2; PTGS2; PTGS2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |